M
Michael A. Palladino
Researcher at Nereus Pharmaceuticals
Publications - 177
Citations - 19198
Michael A. Palladino is an academic researcher from Nereus Pharmaceuticals. The author has contributed to research in topics: Proteasome inhibitor & Bortezomib. The author has an hindex of 57, co-authored 176 publications receiving 18857 citations. Previous affiliations of Michael A. Palladino include Genentech & Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Selective activation of liver X receptors by acanthoic acid-related diterpenes.
Paqui G. Través,Sonsoles Hortelano,Miriam Zeini,Ta-Hsiang Chao,Thanh Lam,Saskia T. C. Neuteboom,Emmanuel A. Theodorakis,Michael A. Palladino,Antonio Castrillo,Lisardo Boscá +9 more
TL;DR: Results show the ability of certain acanthoic acid diterpenes to activate efficiently both LXRs and suggest that these compounds can exert beneficial effects from a cardiovascular standpoint through LXR-dependent mechanisms.
Journal ArticleDOI
Synthesis and structure-activity relationships of benzophenone-bearing diketopiperazine-type anti-microtubule agents.
Yuri Yamazaki,Makiko Sumikura,Yurika Masuda,Yoshiki Hayashi,Hiroyuki Yasui,Yoshiaki Kiso,Takumi Chinen,Takeo Usui,Fumika Yakushiji,Barbara C. M. Potts,Saskia T. C. Neuteboom,Michael A. Palladino,G. K. Lloyd,Yoshio Hayashi,Yoshio Hayashi +14 more
TL;DR: KPU-105 (4), a potent anti-microtubule agent that contains a benzophenone was derived from the diketopiperazine-type vascular disrupting agent (VDA) plinabulin 3, which displays colchicine-like tubulin depolymerization activity, was modified and obtained a 4-fluorobenzophenone derivative 16j that inhibited tumor cell growth in vitro with a subnanomolar IC(50) value.
Patent
Antibodies against type 2 tumor necrosis factor receptor
TL;DR: In this article, the use of monoclonal antibodies against type 2 tumor necrosis factor receptor (TN-R2) for the stimulation of human T-cell proliferation is described.
Patent
Gamma interferon-interleukin-2 synergism
TL;DR: In this article, compositions containing therapeutically synergistic mixtures of purified gamma interferon and purified interleukin-2 are provided for treatment of tumor-bearing hosts.
Patent
Analogs of dehydrophenylahistins and their therapeutic use
TL;DR: In this article, compositions and methods for treating various disease conditions including cancer and non-cancer diseases associated with vascular proliferation are also disclosed, as well as methods for making such compounds.